Header Logo

Connection

ROBERT F GAGEL to Carcinoma, Neuroendocrine

Back to Details
This is a "connection" page, showing publications ROBERT F GAGEL has written about Carcinoma, Neuroendocrine.
ROBERT F GAGEL
Connection Strength
2.442
Carcinoma, Neuroendocrine
  1. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther. 2021 04; 20(4):665-675.
    View in: PubMed
    Score: 0.496
  2. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocr Relat Cancer. 2019 02 01; 26(2):241-250.
    View in: PubMed
    Score: 0.432
  3. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer. J Clin Endocrinol Metab. 2017 03 01; 102(3):933-941.
    View in: PubMed
    Score: 0.378
  4. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma. Recent Results Cancer Res. 2015; 204:227-49.
    View in: PubMed
    Score: 0.325
  5. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs. Endocr Relat Cancer. 2020 08; 27(8):T27-T39.
    View in: PubMed
    Score: 0.120
  6. Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care. 2019 06; 42(6):1075-1080.
    View in: PubMed
    Score: 0.110
  7. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol. 2018 May; 25(5):1395-1402.
    View in: PubMed
    Score: 0.101
  8. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab. 2017 08 01; 102(8):2807-2813.
    View in: PubMed
    Score: 0.097
  9. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. Thyroid. 2016 11; 26(11):1553-1562.
    View in: PubMed
    Score: 0.092
  10. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2016 12; 101(12):4871-4877.
    View in: PubMed
    Score: 0.092
  11. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun; 25(6):567-610.
    View in: PubMed
    Score: 0.084
  12. Activation of G-protein-coupled receptors and thyroid malignant tumors: the jury is still out. Endocr Pract. 2011 Nov-Dec; 17(6):957-9.
    View in: PubMed
    Score: 0.065
  13. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013 Nov; 98(11):E1813-9.
    View in: PubMed
    Score: 0.019
  14. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10; 30(2):134-41.
    View in: PubMed
    Score: 0.016
  15. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.